Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0391
Trial ID NCT03310619
Disease Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017
Co-treatment Durvalumab
Location approved US, Japan, EU, Switzerland, UK, Canada
Generation2nd
PhasePhase1|Phase2
Recruitment statusCompleted
TitleA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
Year2017
CountryUnited States
Company sponsorCelgene
Other ID(s)JCAR017-BCM-002|U1111-1201-2046
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti‐CD19 single‐chain variable fragment; 4‐1BB costimulatory motif; CD3ζ T‐cell activation domain

Clinical Result

Cohort1: JCAR017_Durvalumab
Administration route intravenous infusion
Dosage 50E6 cells, 100E6 cells
Donor type Autologous
Pts 14
Age Adult, Older_Adult
Outcome 71.4%(CR,3 Months), 78.6%(CR,6 Months)
Adverse reactions 7/11(All-couse mortality); 4/11(Blood and lymphatic system disorders; General disorders; Infections and infestations; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders)
Cohort2: JCAR017_CC-122
Administration route intravenous infusion
Dosage 100E6 cells
Donor type Autologous
Pts 8
Age Adult, Older_Adult
Outcome 62.5%(CR,3 Months), 62.5%(CR,6 Months)
Adverse reactions 8/13(All-couse mortality); 7/13(Blood and lymphatic system disorders; Gastrointestinal disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Metabolism and nutrition disorders; Nervous system disorders)
Cohort3: JCAR017_CC-220
Administration route intravenous infusion
Dosage 100E6 cells
Donor type Autologous
Pts 1
Age Adult, Older_Adult
Outcome 0.0%(CR,3 Months), 0.0%(CR,6 Months)
Adverse reactions 1/1(All-couse mortality); 1/1(General disorders; )
Cohort4: JCAR017_Ibrutinib
Administration route intravenous infusion
Dosage 100E6 cells
Donor type Autologous
Pts 15
Age Adult, Older_Adult
Outcome 46.7%(CR,3 Months), 53.3%(CR,6 Months)
Adverse reactions 5/17(All-couse mortality); 6/17(Blood and lymphatic system disorders; Gastrointestinal disorders; Infections and infestations; Nervous system disorders; Respiratory, thoracic and mediastinal disorders)
Cohort5: JCAR017_Relatlimab_Nivolumab
Administration route intravenous infusion
Dosage 100E6 cells
Donor type Autologous
Pts 2
Age Adult, Older_Adult
Outcome 0.0%(CR,3 Months), 0.0%(CR,6 Months)
Adverse reactions 1/2(All-couse mortality); 2/2(Gastrointestinal disorders; Nervous system disorders; )
Cohort6: JCAR017_CC-99282
Administration route intravenous infusion
Dosage 100E6 cells
Donor type Autologous
Pts 5
Age Adult, Older_Adult
Outcome 60.0%(CR,3 Months), 60.0%(CR,6 Months)
Adverse reactions 4/7(All-couse mortality); 3/7(Infections and infestations; Nervous system disorders)

Relationship Graph

Overview of Knowledge Graph